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AbstrACt
Introduction This article describes two randomised 
controlled trials that will evaluate the effectiveness and 
cost-effectiveness of Self-Help Plus (SH+), a group self-
help intervention developed by the WHO to reduce distress. 
In these trials SH+ is being tested as a preventative 
intervention to lower the incidence of mental disorders in 
asylum seekers and refugees with psychological distress 
resettled in Europe and Turkey.
Methods and analysis Two prospective, multicentre, 
randomised, rater-blinded, parallel-group studies will 
follow participants over a period of 12 months. One trial 
will be conducted in Europe and one in Turkey. In each 
trial, 600 asylum seekers and refugees screening positive 
on the General Health Questionnaire (≥3), but without a 
formal diagnosis of any mental disorders according to 
the Mini International Neuropsychiatric Interview, will be 
randomly allocated to SH+or to enhanced treatment-as-
usual. The primary outcome will be a lower incidence 
of mental disorders at 6 month follow-up. Secondary 
outcomes will include the evaluation of psychological 
symptoms, functioning, well-being, treatment acceptability 
and indicators of intervention cost-effectiveness.
Ethics and dissemination The two trials received 
ethical clearance from the local Ethics Committees of the 
participating sites (seven sites), as well as from the WHO 
Ethics Committee. All participants will provide informed 
consent before screening and before study inclusion 
(a two-step procedure). The results of the trials will be 
disseminated in agreement with a dissemination plan 
that includes publication(s) in peer-reviewed journals 
and presentations at relevant national and international 
conferences and meetings.
trials registration numbers NCT03571347, 
NCT03587896.
IntroduCtIon
background and rationale
The number of people seeking refugee status 
in European and bordering countries has 
progressively increased in recent years, driven 
by the wars in Syria, Afghanistan and Iraq, 
alongside conflicts and instability in Afghan-
istan and elsewhere.1–3 These populations 
face numerous challenges before, during 
and after migration.4–8 Refugees and asylum 
seekers are exposed to multiple stressors in 
their native countries (eg, war-related experi-
ences, violence, destructions of their homes). 
strengths and limitations of this study
 ► Interventions for preventing mental disorders are a 
public health priority.
 ► Evaluating the effectiveness of a low-intensity group 
self-help intervention is particularly relevant in 
emergency and limited-resource settings.
 ► Conducting research with populations in transit is 
challenging, as participants might not be traceable 
at follow-up and may not be interested in participat-
ing in clinical studies.
 ► The possibility of contamination between the ex-
perimental and control arms cannot be excluded, as 
randomisation will occur at the individual level.
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They are also exposed to many stressors during migra-
tion.6 9 After arriving in host countries, they may then 
face additional challenges and perceived discrimination 
due to language barriers, loss of family and community 
support, poverty, lack of access to social, educational and 
healthcare institutions and uncertain asylum application 
procedures.10 11 
These factors place refugees and asylum seekers at 
considerable risk for developing common mental disor-
ders, including post-traumatic stress disorder (PTSD), 
anxiety disorders and depressive disorders and other 
forms of disabling psychological distress.12 13
There is a growing body of research demonstrating the 
effectiveness of psychological therapies for refugees and 
asylum seekers.12 14 A recently-published umbrella review 
of systematic reviews on this topic showed encouraging 
results in terms of reduction of depression, PTSD and 
other anxiety symptoms.12 However, treatments typically 
require extensive training and supervision, and sufficient 
time to be delivered in full (eg, up to 12 weeks). Addition-
ally, most interventions targeted the symptoms of mental 
disorders, without a specific focus on prevention.8 12 15–17
Recently, the WHO has developed a novel, low-inten-
sity five-session self-help intervention for managing stress 
and coping with adversity, which is designed to be deliv-
ered by non-specialist facilitators and does not require 
extensive training.18 This psychosocial intervention, 
called Self-Help Plus (SH+), is intended to help people 
with and without mental disorders to cope with distress 
stemming from diverse types of adversity. SH+ has already 
been tested in small pilot studies19 20 and a large positive 
randomised controlled trial (RCT) with South Sudanese 
female refugees in Uganda.19 20 SH+ has not been tested 
as a preventive intervention.
In order to fill this gap, two RCTs were designed to test 
SH+ as an indicated preventive intervention with asylum 
seekers and refugees resettled in European countries and 
in Turkey. The choice of conducting two separate trials is 
mainly due to the type of setting and the different travel-
ling experiences of asylum seekers and refugees.
Aim and objectives
The overall aim of these RCTs is to evaluate the effective-
ness and cost-effectiveness of SH+ as an indicated preven-
tive intervention in asylum seekers and refugees with 
psychological distress resettled in six sites of five European 
countries (Italy, Austria, Germany, Finland and two sites 
in the UK), and in Turkey, as compared with enhanced 
treatment as usual (ETAU). The primary objective is the 
reduction in the incidence of any mental disorder at 
6 month follow-up. Secondary objectives are the evalua-
tion of psychological symptoms, functioning, well-being, 
treatment acceptability and economical outcomes.
study hypotheses
1. SH+ will be superior to ETAU in preventing the onset 
of any mental disorder at 6 month follow-up.
2. Compared with the ETAU group, asylum seekers and 
refugees in the SH+ intervention arm will report an 
improvement in depression, anxiety and PTSD symp-
toms, psychosocial well-being and improved levels of 
psychological functioning.
3. Asylum seekers and refugees in the SH+ interven-
tion arm will incur lower healthcare costs compared 
with the ETAU group.
MEthods And AnAlysEs
These are two prospective, multicentre, randomised, 
parallel-group studies that will follow participants over a 
period of 12 months. Figure 1 provides a flow-chart of the 
RCT’s process.
Refugees and asylum seekers with psychological 
distress as assessed by the General Health Question-
naire (GHQ),21 but without a mental disorder according 
to the Mini International Neuropsychiatric Interview 
(M.I.N.I.)22 for the Diagnostic and Statistical Manual of 
Mental Disorders, fifth edition (DSM-5)23 and the Inter-
national Classification of Diseases, tenth edition (ICD-
10) classification of mental and behavioural disorders,24 
will be randomly assigned to SH+ or ETAU. Participants 
will be assessed at baseline before randomisation, imme-
diately post-intervention, and at 6 and 12 months of 
follow-up. The two RCTs will be conducted in accordance 
Figure 1 RCT flow diagram. ETAU, enhanced treatment as 
usual; RCT, randomised controlled trial; SH+, Self-Help Plus. 
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to the Consolidated Standards of Reporting Trials state-
ment.25 26
Inclusion criteria
a. Age 18 or above;
b. Able to speak and understand one of the languages in 
which SH+ has been adapted: Arabic, Dari, Urdu or 
English;
c. Asylum seeker or refugee or person under temporary 
protection;
d. Presence of psychological distress, as shown by a score 
of 3 or more on the 12-item GHQ-12;
e. Both oral and written informed consent to enter the 
study.
Exclusion criteria
a. Presence of any mental disorders according to DSM-5 
and ICD-10, as shown by a positive M.I.N.I.;
b. Acute medical conditions contraindicating study par-
ticipation, based on the clinical judgement of the 
healthcare professional or trained paraprofessional 
who performs the screening;
c. Clinical evidence of imminent suicide risk or suicide 
risk scored as ‘moderate or high’ (or a positive sui-
cidality behaviour disorder) by the M.I.N.I. (section 
Suicidality);
d. Clinical evidence that decision-making capacity is 
impaired.
Asylum seekers and refugees that are excluded because 
of a diagnosis of a mental disorder will be advised to 
seek professional treatment according to a pre-defined 
protocol.
Two experts giving advice on any ethical issues related 
to the trials were appointed to be members of an Ethics 
Advisory Board (EAB). Additionally, a data protection 
officer was appointed to supervise and report that data 
collection is carried out according to European and 
national legislations.
Characteristics of the intervention
The SH+ programme has been developed by WHO 
and collaborators working in the humanitarian field. 
SH+ consists of a pre-recorded audio course, delivered by 
facilitators in a group setting and complemented with an 
illustrated self-help book. The potential value of using a 
psychoeducational course to access hard-to-reach popula-
tions has been shown previously.27 Evidence for the use of 
books in interventions is also promising.28 Furthermore, 
research has found that guided self-help programmes 
produce much better results than ‘pure’ self-help, and 
the effects produced are similar to face-to-face psycholog-
ical treatment.29 SH+ was designed to be relevant for large 
segments of adversity-affected populations: it is intended 
to be transdiagnostical, easily adaptable to different 
cultures and languages and both meaningful and safe for 
people with and without mental disorders.
The format of SH+ is innovative in that it seeks to 
ensure that key intervention components are delivered 
as intended without the burden of extensive facilitator 
training. The SH+ programme is based on acceptance 
and commitment therapy (ACT), a form of cogni-
tive-behavioural therapy, with distinct features.30 ACT is 
based on the concept that ongoing attempts to suppress 
unwanted thoughts and feelings can paradoxically make 
these problems worse. Instead, it emphasises learning 
new ways to accommodate difficult thoughts and feel-
ings, while guiding people to take proactive steps towards 
living in a way that is consistent with their values. ACT 
has been shown to be useful for a range of mental health 
issues31 and has been used successfully in a guided self-
help format.32 SH+ includes ACT techniques that aim to 
help people cope with stress, respond compassionately 
to themselves and others and to live in accordance with 
their values.
The SH+ programme has two components: a pre-re-
corded course and an illustrated self-help book. Pre-re-
corded audio material is delivered across five 2 hour 
sessions to groups of up to 30 people. The audio material 
imparts key information about stress management and 
guides participants through individual exercises and small 
group discussions. To augment the audio recordings, an 
illustrated self-help book reviews all essential content and 
concepts.18 Written manuals help non-specialist facilita-
tors to conduct the course using the pre-recorded audio.
Delivery of SH+
SH+ will be delivered by briefly-trained, non-specialist 
facilitators with a refugee or migrant background. 
SH+ trainers will be academics and/or mental health-
care professionals. Before the recruitment period, 
SH+ trainers received specific training on the SH+ inter-
vention from WHO.
SH+ has been adapted into Arabic, Dari and Urdu 
according to the WHO Department of Mental Health 
and Substance Abuse draft protocol for adapting 
psychological interventions for common mental health 
problems. An English version is also available, which has 
been translated into the other languages with a focus 
on ensuring the translated version text and images are 
acceptable, understandable and relevant to the popula-
tion. Close attention was paid to the form of language 
(eg, colloquial) and tone (eg, warm and caring) so that 
it may be fully suitable for a pre-recorded audio psycho-
logical intervention. The SH+ audio and book were 
reviewed and revised by native speakers with diverse 
backgrounds.
Enhanced treatment as usual
Control arm participants will receive routine social 
support and/or care following local regulations. Addi-
tionally, they will receive baseline and follow-up assess-
ments according to the study schedule; information about 
freely available health and social services, and community 
networks that provide support to refugees and asylum 
seekers.
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Primary and secondary outcomes
Outcome measures and time points are detailed in 
table 1. The primary outcome will be the incidence 
of any mental disorders measured by the M.I.N.I. at 
6 month follow-up. All other measures will be secondary 
outcomes.
randomisation
Randomisation will occur at the individual level and will be 
stratified by each recruiting centre. To avoid contamina-
tion, only one person per household will be randomised. 
Randomisation will be centralised and coordinated by the 
WHO Collaborating Centre of the University of Verona. 
Eligible participants will be randomly assigned to one of 
the two groups with an equal probability of assignment 
to each group (allocation ratio 1:1). The randomisation 
schedule will be generated using the web-based soft-
ware Castor Electronic Data Capture.33 This electronic 
tool employs a variable block randomisation method, in 
order to allocate groups randomly permuted in blocks 
of unequal size. The site investigators will not know the 
block size and will not be able to access the randomis-
ation list. The randomisation list will be accessible only 
to the data manager. In addition, the web-based software 
will allow random allocation only after the main informa-
tion on the enrolled participant is entered, on verifica-
tion of the inclusion criteria. After random allocation, 
the software will produce a unique identification number 
for each participant. In accordance with the Declaration 
of Helsinki,34 the participants’ confidentiality will be 
preserved at all times and the contents of the recruitment 
Table 1 Outcome measures and time points
Concept Screening Baseline
Post- 
intervention
6 month follow-
up
12 month follow-
up
Informed consent Informed consent Randomisation 
Mental capacity Mental capacity 
form
Mental capacity 
form
Mental capacity 
form
Mental capacity 
form
Mental capacity 
form
Psychological 
distress
GHQ-12 GHQ-12 GHQ-12 GHQ-12
Psychiatric 
diagnosis
M.I.N.I. M.I.N.I. M.I.N.I. M.I.N.I. 
Socio-
demographical 
and migration 
data
Recruitment form
Symptoms of 
PTSD
PCL-5 PCL-5 PCL-5 PCL-5
Depressive 
symptoms
PHQ-9 PHQ-9 PHQ-9 PHQ-9
Adverse life 
events
HTQ –Part A/1
Subjective well-
being
WHO-5
Well-being index
WHO-5
Well-being index
WHO-5
Well-being index
WHO-5
Well-being index
Health-related 
quality of life
EQ-5D-3L EQ-5D-3L EQ-5D-3L
Self-defined 
psychosocial 
goals
PSYCHLOPS
(pre-int. version)
PSYCHLOPS
(post-int. 
version)
PSYCHLOPS
(post-int. version)
PSYCHLOPS
(post-int. version)
Post migration 
stress difficulties
PMLD PMLD PMLD
Psychological 
functioning
WHODAS 2.0 WHODAS 2.0 WHODAS 2.0 WHODAS 2.0
Cost-
effectiveness
CSSRI-EU CSSRI-EU CSSRI-EU
Adverse events Adverse events form
CSSRI-EU, Client Socio-Demographic and Service Receipt Inventory, European Version; DSM-5, Diagnostic and Statistical Manual 
of Mental Disorders, fifth edition; GHQ-12, General Health Questionnaire-12 items; HTQ, Harvard Trauma Questionnaire; int., 
intervention; MINI, Mini International Neuropsychiatric Interview; PCL-5, PTSD Checklist for DSM-5; PHQ-9, Patient Health 
Questionnaire–9 items; PMLD, post-migration living difficulties; PSYCHLOPS, Psychological Outcome Profiles Instrument; PTSD, 
Post-Traumatic Stress Disorder; WHO-5, World Health Organization–5 items; EQ-5D-3L, Three-level version of EuroQol Group; 
WHODAS, World Health Organization Disability Assessment Schedule.
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and follow-up forms will not be disclosed to any third 
party.
Masking
Masking participants and facilitators about the interven-
tion status will be impossible, due to the nature of the 
intervention. However, investigators evaluating primary 
and secondary outcomes post-intervention and at 6 and 
12 month follow-up, and the statistician performing all 
analyses, will be masked to the participants’ allocation 
status. Healthcare professionals and cultural mediators 
involved in the assessments will be instructed on how to 
perform follow-up assessments in order to preserve effec-
tive masking.
sample size and power calculations
On the basis of data extrapolated from prevention 
trials, an event rate (diagnosis of any mental disor-
ders) of around 15% at 6 months (primary outcome) 
is expected.35 36 However, these prevention trials were 
conducted in unselected populations that were not 
exposed to migration stressors. By contrast, refugees 
and asylum seekers are exposed to stressors that are 
associated with increased rates of mental disorders.8 
On these grounds, we anticipate an incidence rate 
of mental disorders of 25% at 6 months in this popu-
lation. It is hypothesised that the provision of the 
SH+ programme will show a clinically significant advan-
tage by producing a between-groups absolute differ-
ence of 10%. A sample size of 500 participants per trial, 
achieves 80% power for a 0.05 level of significance 
between the two proportions of people diagnosed with 
mental disorders at 6 months. Assuming that a relevant 
proportion of asylum seekers and refugees might be 
lost at study endpoint (due to the specific characteris-
tics of this population), the final sample size will be of 
600 participants (300 in each group) for the European 
trial and 600 participants (300 in each group) for the 
Turkish trial. We anticipate that we will screen around 
1800 to 2000 people to have 600 eligible participants.
Adverse events reporting
Serious adverse events and other adverse events 
reported spontaneously by the participants or observed 
by the research staff will be recorded on a specifically 
developed form. Data on the relationship with the study 
intervention, the action taken regarding intervention 
and the outcome of the adverse event, will be collected. 
An event is considered a potential adverse reaction if it 
is an undesirable experience occurring to a participant 
during the study, whether or not it is considered related 
to the research procedure. This definition includes all 
aspects of mental health and psychological functioning, 
but also any other undesirable experiences. The EAB 
will review spontaneously reported serious adverse 
reactions (eg, suicide attempts) within 48 hours, while 
general adverse reactions will be reviewed by the EAB 
in regular meetings.
data management and statistical analysis
Statistical analysis
General approach
The statistical analysis will be masked. All analyses will be 
performed using Stata/SE, Release 14.2.
Two data locks will occur during the study. The first will 
happen 6 months after the end of the 12 month enrolment 
period, when information on the primary outcome and 
on short-term secondary outcomes will be available for all 
the participants. The second will happen 12 months after 
the end of the 12 month enrolment period. All primary 
and secondary analyses will be performed on an inten-
tion-to-treat (ITT) basis. The ITT population will consist 
of all participants randomly assigned to the competing 
intervention strategies, and with data on the baseline 
assessment available. In order to check the robustness of 
results, the primary outcome will be additionally analysed 
using a per protocol (PP) approach, that will include only 
SH+ participants who attended at least three sessions. 
The analysis of the PP population will be used for confir-
matory purposes only. If less than 5% of participants do 
not receive the allocated intervention according to the 
study protocol, the PP analysis will not be performed. All 
analyses reaching statistical significance will be replicated 
for each recruiting centre and for each target language 
separately.
Analysis of the primary outcome
The proportion of participants with a diagnosis of any 
mental disorders at 6 months follow-up will be compared 
between the two groups using a chi-square test (primary 
analysis). A multivariate analysis (secondary analysis) will 
be performed through a Poisson regression model, with 
robust error variance,34 to estimate relative risks directly 
and to explore the potential confounding effect of prog-
nostic factors, and the interactions with treatment.
Analysis of the secondary outcomes
The proportion of participants with a diagnosis of any 
mental disorder post-intervention and at 12 months of 
follow-up will be compared between the two groups using 
a X2 test. A multivariate analysis will be performed using a 
Poisson regression model, with a robust error variance, to 
estimate relative risks directly and to explore the poten-
tial confounding effect of prognostic factors, and the 
interactions with treatment.37
Analysis of GHQ-12, WHODAS 2.0, PHQ-9, WHO-5 Well-being 
index, PSYCHLOPS, PCL-5
For each questionnaire, in case of missing items, the 
corrected item mean substitution method,38 will be used 
(ie, the item mean across participants weighted by the 
subject’s mean of completed items), using information 
from subjects belonging to the same treatment arm for the 
same follow-up time. The hypothesis that the experimental 
intervention has no effect on GHQ-12, World Health 
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Organisation Disability Assessment Schedule (WHODAS) 
2.0, Patient Health Questionnaire–9 items (PHQ-9), 
WHO-5 Well-being index, Psychological Outcome Profiles 
Instrument (PSYCHLOPS), PTSD Checklist for DSM-5 
(PCL-5) scores will be tested by performing seemingly 
unrelated regression,39 for each time point, controlling 
for baseline values. In case of joint statistical significance 
of the coefficients related to treatment status, the effect 
of treatment on each score will be evaluated through a 
mixed analysis of covariance (ANCOVA), controlling for 
the value at baseline. After the last data lock, ANCOVA 
with robust standard errors will be performed for each 
scale, using the values at post-intervention, and at 6 and 
12 months follow-up, controlling for the value at baseline. 
In case of joint statistical significance of the coefficients 
related to treatment status, the analysis will be repeated 
for each outcome/time combination. Such approaches 
(assessing the global significance of all time locks for each 
scale, without imputing missing values) will allow to have 
a robustness check to results obtained after each time 
point. As a further sensitivity check, multivariate analyses 
will be performed for each scale to take confounding 
factors into account, again including the baseline value 
as a covariate.
The proportion of participants leaving the study early 
will be compared between the two groups using a X2 test 
(or the Fisher exact test, where appropriate). A multivar-
iate analysis will be performed using a Poisson regression 
model, with a robust error variance, to estimate relative 
risks directly and to explore the potential confounding 
effect of prognostic factors, and the interactions with 
treatment.37
Cost-effectiveness analysis
Incremental cost-effectiveness analyses (ICEA) will 
be conducted from the health and social care system 
perspective and from the societal perspective by means 
of the net-benefit approach.40 For the five European 
countries the ICEA will be conducted from the perspec-
tive of the UK healthcare system and for Turkey from 
the perspective of the Turkish healthcare system. Direct 
costs including formal medical and psychiatric health-
care, psychosocial care, legal services and informal 
services will be used for ICEA from the health and social 
care system (payer) perspective. Total costs will be used 
for ICEA from the societal perspective. Comprehen-
sive use of annual health and social care resources will 
be assessed by means of completing the adapted Client 
Socio-Demographic and Service Receipt Inventory, 
European Version. Information on the unit-costs of the 
used services for the European countries will be gained 
by the cost compilation for the UK health and social 
care system.41 For Turkey, price lists and other sources 
will be used to identify unit costs. Costs of informal 
services will be estimated for both studies on the basis 
of average salaries per hour. Total direct costs of service 
use will be calculated by multiplying service units with 
unit costs. Annual total costs of mental illness will be 
estimated on the basis of two retrospective assessments of 
6 month service use at 6 and 12 month follow-up. Produc-
tivity losses will be estimated for participants with work 
permissions by means of the human capital approach42 
on the basis of group-specific average salaries. Costs for 
the European countries will be calculated in 2017 UK £. 
Costs for Turkey will be calculated in Turkish Lira. Total 
costs of health and social care service use will be inves-
tigated with regard to the cost driving effects of asylum 
seekers and refugees characteristics and the impact of 
different levels of coverage, different macroeconomical, 
social and healthcare indicators by estimating regression 
based cost functions.43 Incremental net monetary benefit 
(NMB) will be computed by regressing the NMB on study 
group.44 Results of ICEA for the European countries will 
be interpreted according to UK marginal willingness to 
pay  (MWTP) thresholds recommended by the National 
Institute for Health and Care Excellence (NICE).45 
Results for Turkey will be interpreted according to the 
three times gross domestic product per capita threshold46 
and alternatively by country-specific thresholds provided 
by Woods et al.47 For international comparison all cost 
data and results of ICEA will be converted into € and 
US$ adjusted for power purchasing parities.
Patient and public involvement
Participants have not been involved in the design of the 
study. However, SH+ facilitators delivering the inter-
vention will be refugees or community members with a 
refugee or migrant background or with the same/similar 
culture of participants. They will have some prior expe-
rience in health or social or community work or volun-
teering. The choice of asylum seekers’ and refugees’ 
country of origin was made in accordance with a situa-
tional analysis on size of refugee populations within Euro-
pean countries and Turkey, as well as feasibility issues.
Ethics and dissemination
It is essential to conduct this research because rigorous 
evidence needs to be collected on the effectiveness of the 
SH+ intervention, which has been specifically developed 
for vulnerable populations. Additionally, it will provide 
valuable information about optimal adaptation strategies 
and aspects to consider when scaling up the intervention 
in diverse contexts.
The trials will be conducted according to globally 
accepted standards of good clinical practice (as defined 
in the ICH E6 Guideline for Good Clinical Practice, 1 
May 1996), in agreement with the Declaration of Helsinki 
and in keeping with local regulations.
Dissemination includes a publication plan agreed by all 
members of the consortium that regulates academic arti-
cles and conference presentations. On the basis of positive 
results from research trials of SH+, the SH+ package will 
be disseminated by WHO in multiple languages. Any 
protocol modifications will be submitted to local Ethics 
Committess for approval.
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dIsCussIon
This article presents the main characteristics of two RCTs, 
which will assess the effectiveness and cost-effective-
ness of a low-intensity self-help intervention to prevent 
mental disorders among distressed refugees and asylum 
seekers. The concept of low-intensity implies that fewer 
resources are used than in more complex, conventional 
psychosocial treatments. SH+ may be delivered by facilita-
tors without formal mental health professional training, 
employs low-cost technologies, such as audio recordings 
and an illustrated book, has only five sessions and may be 
delivered to groups of up to 30 participants. The group 
setting has the advantage of being scalable and optimising 
resource use, but it has limited scope for in-depth work 
with individuals, and participants exposed to traumatic 
experiences might be concerned about interacting with 
others in a group space.
If positive results from these trials are achieved, WHO 
may adopt and disseminate SH+ as a preventive interven-
tion in multiple languages.
A number of characteristics of the design of these two 
trials may hamper or facilitate their implementation. 
First, the study was designed as two trials with an almost 
identical design, with one conducted in European coun-
tries and one in Turkey. We reasoned that even though 
the population that will be recruited in Turkey shares 
important characteristics with the population in Euro-
pean countries, in terms of pre-migration, migration and 
post migration stressors,5 9 48 the resettlement context is 
likely to be different. This may be relevant for a number 
of aspects, including the definition of the control group, 
which receives treatment as usual enhanced by referral 
mechanisms to social organisations and healthcare facili-
ties. While these mechanisms may show some similarities 
across different European countries, the same may not 
apply for Turkey. The resettlement context may addition-
ally be relevant for the capacity of research staff to follow 
participants, as this aspect may be substantially affected by 
the mobility of the population under study.
Second, a focus on prevention, rather than treatment, 
is challenging. In practical terms, it means recruiting 
participants showing some psychological distress but 
not a mental disorder. This may represent an obstacle to 
recruitment, as at study entry the administration of the 
M.I.N.I., which is of paramount relevance to exclude 
those with a disorder, requires time and training. Addi-
tionally, since participants who screen positive cannot 
be included, we anticipate the need to screen hundreds 
of potential participants to reach the target sample size. 
Another aspect related to the recruitment of participants 
without a disorder is that those eligible for inclusion will 
clearly be less distressed as compared with those suffering 
from a mental disorder. Therefore, eligible participants 
may be less likely to agree to be included, as they may 
feel that dealing with their psychological distress may 
not be as relevant as dealing with other social or health 
aspects. Participants with a mental disorder, by contrast, 
may recognise that dealing with psychological problems 
is a high priority and a pre-requisite for optimal social 
functioning. This may be another obstacle for effective 
recruitment.
Despite these potential challenges, establishing the 
effectiveness of preventive psychosocial interventions is 
a public health priority, as it may help large population 
groups over short periods of time. Preventive psychosocial 
interventions must be feasible, sustainable and cost-effec-
tive. SH+, which is based on self-help approaches, may 
have particular advantages for populations with limited 
access to social and healthcare services, and with high 
levels of need.
ConClusIon
This project aims to generate a strong evidence-base for 
preventative aspects of SH+, and to create a scientific 
framework for adapting and equipping social and health-
care systems in countries inside and outside Europe with 
such a low intensity intervention. The delivery format 
of SH+ is innovative, as it requires a short training of 
non-professional facilitators, and reduced supervision, 
and fidelity is assured by the pre-recorded audio and 
the book. Moreover, the intervention has been culturally 
adapted according to a WHO protocol and cultural adap-
tation will be extended to other population groups after 
publication of the SH+ programme.
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